Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016

  • ID: 3758998
  • Report
  • 63 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Digna Biotech, S.L.
  • UniQure N.V.
  • MORE
Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016

Summary

‘Porphyria (Erythropoietic Protoporphyri) - Pipeline Review, H1 2016’, provides an overview of the Porphyria (Erythropoietic Protoporphyri) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Porphyria (Erythropoietic Protoporphyri), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Porphyria (Erythropoietic Protoporphyri) and features dormant and discontinued projects.

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Porphyria (Erythropoietic Protoporphyri)
- The report reviews pipeline therapeutics for Porphyria (Erythropoietic Protoporphyri) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Porphyria (Erythropoietic Protoporphyri) therapeutics and enlists all their major and minor projects
- The report assesses Porphyria (Erythropoietic Protoporphyri) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Porphyria (Erythropoietic Protoporphyri)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Porphyria (Erythropoietic Protoporphyri)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Porphyria (Erythropoietic Protoporphyri) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Digna Biotech, S.L.
  • UniQure N.V.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Porphyria (Erythropoietic Protoporphyri) Overview

Therapeutics Development

Pipeline Products for Porphyria (Erythropoietic Protoporphyri) - Overview

Pipeline Products for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis

Porphyria (Erythropoietic Protoporphyri) - Therapeutics under Development by Companies

Porphyria (Erythropoietic Protoporphyri) - Therapeutics under Investigation by Universities/Institutes

Porphyria (Erythropoietic Protoporphyri) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Porphyria (Erythropoietic Protoporphyri) - Products under Development by Companies

Porphyria (Erythropoietic Protoporphyri) - Products under Investigation by Universities/Institutes

Porphyria (Erythropoietic Protoporphyri) - Companies Involved in Therapeutics Development

Alnylam Pharmaceuticals, Inc.

Clinuvel Pharmaceuticals Limited

Digna Biotech, S.L.

UniQure N.V.

Porphyria (Erythropoietic Protoporphyri) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

afamelanotide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ALN-AS1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AMT-021 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DB-027 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Enzyme Replacement Therapy for Acute Intermittent Porphyria - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Porphyria (Erythropoietic Protoporphyri) - Recent Pipeline Updates

Porphyria (Erythropoietic Protoporphyri) - Discontinued Products

Porphyria (Erythropoietic Protoporphyri) - Product Development Milestones

Featured News & Press Releases

Mar 24, 2016: NICE’s technical team invited stakeholders with an interest in the treatment of erythropoietic protoporphyria

Feb 16, 2016: Clinuvel brief on European commercialisation

Feb 12, 2016: SCENESSE receives US FDA orphan designation for cutaneous porphyrias

Sep 15, 2015: Alnylam Reports Positive Initial Clinical Results for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 for the Treatment of Acute Hepatic Porphyrias

Aug 27, 2015: FDA grants Clinuvel a Type C Meeting

Jul 02, 2015: New England Journal of Medicine publishes pivotal Phase III SCENESSE studies

Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Causes Extreme Light Sensitivity

Jul 01, 2015: Treatment Reduces Symptoms in Syndrome that Causes Extreme Light Sensitivity

Jun 05, 2015: SCENESSE Commercialisation Update

May 26, 2015: Alnylam Initiates Phase 1 Clinical Trial for ALN-AS1, an Investigational RNAi Therapeutic Targeting Aminolevulinic Acid Synthase 1 (ALAS1) for the Treatment of Acute Hepatic Porphyrias, Including Acute Intermittent Porphyria (AIP)

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Porphyria (Erythropoietic Protoporphyri), H1 2016

Number of Products under Development for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Porphyria (Erythropoietic Protoporphyri) - Pipeline by Alnylam Pharmaceuticals, Inc., H1 2016

Porphyria (Erythropoietic Protoporphyri) - Pipeline by Clinuvel Pharmaceuticals Limited, H1 2016

Porphyria (Erythropoietic Protoporphyri) - Pipeline by Digna Biotech, S.L., H1 2016

Porphyria (Erythropoietic Protoporphyri) - Pipeline by UniQure N.V., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Porphyria (Erythropoietic Protoporphyri) Therapeutics - Recent Pipeline Updates, H1 2016

Porphyria (Erythropoietic Protoporphyri) - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Porphyria (Erythropoietic Protoporphyri), H1 2016

Number of Products under Development for Porphyria (Erythropoietic Protoporphyri) - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Targets, H1 2016

Number of Products by Stage and Targets, H1 2016

Number of Products by Mechanism of Actions, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Alnylam Pharmaceuticals, Inc.
Clinuvel Pharmaceuticals Limited
Digna Biotech, S.L.
UniQure N.V.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll